Latest "Mifepristone Cushing Syndrome" News Stories

04:54 EDT 7th July 2015 | BioPortfolio

Here are the most relevant search results for "Mifepristone Cushing Syndrome" found in our extensive news archives from over 250 global news sources.

More Information about Mifepristone Cushing Syndrome on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Mifepristone Cushing Syndrome for you to read. Along with our medical data and news we also list Mifepristone Cushing Syndrome Clinical Trials, which are updated daily. BioPortfolio also has a large database of Mifepristone Cushing Syndrome Companies for you to search.

Showing "Mifepristone Cushing Syndrome" News Articles 1–25 of 2,200+

Extremely Relevant

Rapid expansion forecast for global Cushing’s syndrome drug market

The global Cushing’s syndrome (CS) treatment market will expand rapidly in value from around $179 million in 2013 to $499 million by 2018, representing an impressive compound annual growth rate (CAGR) of 22.74%, according to a new study.

Relevant

OpportunityAnalyzer: Cushing’s Syndrome - Opportunity Analysis and Forecasts to 2018

Recently added to the BioPortfolio report store, OpportunityAnalyzer: Cushing’s Syndrome - Opportunity Analysis and Forecasts to 2018 is a new report from GlobalData published on 2015-01-08. This 194-page report is available in PDF from $4650. OpportunityAnalyzer: Cushing’s Syndrome - Opportunity Analysis and Forecasts to 2018 Summary GlobalData estimates that the 2013 sales for the Cushing...

Speculative Thoughts Corcept Therapeutics (CORT)

In recent posting, we have characterized Corcept as a surprising “comeback’ story. The stock is trading near levels seen before last May’s disappointing Phase III trial results for psychotic depression.Corcept recently gave guidance of $47M to $53M in 2015 sales for Korlym (AKA mifepristone) to treat Cushing’s syndrome.

Quotient Clinical Delivers First In-human Program for Corcept Therapeutics

Focus is on treatment of Cushing’s syndrome and certain cancers

Corcept Therapeutics (CORT) - ASCO Abstract on Mifepristone to treat Breast Cancer

On the evening of May 13, 2015, a press release was published about Corcept’s current Phase I/II trial of mifepristone

Thoughts on Corcept Therapeutics' (CORT) Update

On Thursday, January 29, 2015, Corcept Therapeutics reported Q4 and FY 2014 revenue and held a conference call. In sum, we were treated to a positive outlook, more than we had previously anticipated.     Corcept continues to report increasing sales of Korlym     Korlym sales are projected to roughly double for 2015

Corcept Therapeutics Announces Poster Presentations on Mifepristone for the Treatment of Patients With Cushing's Syndrome at the 27th Annual American Association of Clinical Endocrinologists

MENLO PARK, CA -- (Marketwired) -- 05/14/15 -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, oncologic and psychiatric disorders, today announced that four posters about mifepristone will be presented at the 24th annual American Association of Clinical Endocrino...

Corcept Therapeutics Announces Nine Poster Presentations on Mifepristone for the Treatment of Cushing's Syndrome at the 97th Annual Endocrine Society Meeting

MENLO PARK, CA -- (Marketwired) -- 03/05/15 -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, oncologic and psychiatric disorders, today announced that a variety of posters about Korlym® (mifepristone) will be presented at the 97th annual Endocrine Society Meeti...

A C-terminal HSP90 inhibitor restores glucocorticoid sensitivity and relieves a mouse allograft model of Cushing disease

Inhibition of Hsp90 as its C-terminus allows for the mature folding of GR and its full activity, thus ameliorating Cushing symptoms in a mouse model.

Corcept (CORT) - Thots on Korlym's Cancer Trials - ASCO Abstract

On the evening of May 13, 2015, a press release was published about Corcept’s current Phase I/II trial of mifepristone

Rethinking Corcept Therapeutics (CORT), Part III of IV: Introduction to the New Pipeline

Rethinking Corcept: The Upcoming Pipeline It’s still early in Corcept’s portfolio development but important phase II trials are ongoing with independent investigators. Results should arrive over the next 15 to 18 months and will enable Corcept to select for its current basket of development targets. We think this includes:

Cortendo AB: COR-003 Phase 3 Study Protocol to Be Presented at ENDO 2015: The Endocrine Society’s 97th Annual Meeting & Expo

Regulatory News: Cortendo AB  [ticker: CORT on NOTC-A], a global biopharmaceutical company initially focused on orphan endocrine disorders, today announced that it will present the study protocol of its global Phase 3 study of COR-003 in patients with endogenous Cushing’s syndrome at ENDO 2015: The Endocrine Society’s 97th Annual Meeting &...

Corcept Therapeutics (CORT) Releases Q4 2014 Financials and Update

On March 4, 2015, Corcept Therapeutics (CORT) released its quarterly financial results for Q4 2014 and provided a clinical update. In the earlier release, Corcept provided limited data and sales guidance for 2015.The effect of increasing sales on the financial metrics is immediately apparent.  While net sales was only $26.6M for 2014, it made a significant difference. The net loss was $3.9M f...

PIPE brings in SEK221mm for Cortendo

Cortendo AB (developing therapies for orphan endocrine disorders) raised SEK221mm ($26.2mm) through the placement of 52.3mm shares at SEK4.22 (a 48% discount) to RA Capital Management, New Enterprise Associates, Broadfin Capital, and HealthCap. Funds...

COR-003 Phase 3 Study Protocol to be Presented at ENDO 2015: The Endocrine Society’s 97th Annual Meeting & Expo

Cortendo AB [ticker: CORT on NOTC-A], a global biopharmaceutical company initially focused on orphan endocrine disorders, today announced that it will present the study protocol of its global Phase 3 study of COR-003 in patients with endogenous Cushing’s syndrome at ENDO 2015: The Endocrine Society’s 97th Annual Meeting & Expo March 5-8 in San Dieg...

Rethinking Corcept Therapeutics (CORT), Part III of IV: Introduction to the Future Pipeline

Rethinking Corcept: The Upcoming Pipeline Important phase II trials are ongoing with independent investigators. These results should arrive over the next 15 to 18 months and enable Corcept creates a new basket of development targets. We think this includes:

Mifepristone: Interim Phase I/II data

Rethinking Corcept Therapeutics (CORT), Part I of III: Thinking about Cancer

The New BioWatch Team recently visited CEO Joe Belanoff at the Corcept HQ in Menlo Park, CA. We wanted to follow-up on the recent Q1 2015 conference call as well as extend our own thinking regarding Corcept.We have separated this into three parts: Part I is focused on

Corcept Therapeutics - $17.2M From Exercise of Outstanding Warrants + Additional Thoughts

On Wednesday April 1, 2015, Corcept Therapeutics announced gross receipt of $17.2M from the exercise of warrants. This gives Corcept much needed breathing room. With the additional cash, we guesstimate that Corcept currently has about $37M in cash.The table below summarizes all the warrants outstanding for Corcept at the end of 2014. As of December 31, 2014

Quotient delivers breakthrough first-in-human program for Corcept

Quotient Clinical announced the successful completion of an Enabled-First-in-Human® program for U.S. biotech company Corcept Therapeutics. The program focused on a next generation selective glucocorticoid receptor antagonist (CORT125134) in developm...

Corcept Therapeutics - $17.2M From Exercise of Outstanding Warrants

On Wednesday April 1, 2015, Corcept Therapeutics announced gross receipt of $17.2M from the exercise of warrants. This gives Corcept much needed breathing room. We guesstimate that Corcept currently has about $37M in cash.The table below summarizes all the warrants outstanding for Corcept at the end of 2014. As of December 31, 2014

Celebrating the Biomedical Achievements on World Down Syndrome Day

Guest Post by Sara Hart Weir, MS, President, National Down Syndrome Society On March 21, we celebrate the 10th Annual World Down Syndrome Day.  It was established and eventually recognized by the United Nations as a means to raise awareness and mo...

New Tool for Down Syndrome Research

Researchers, clinicians, and other professionals with an interest in Down syndrome can now access deidentified data from DS-Connect: The Down Syndrome Registry, where people in the Down syndrome community voluntarily and securely store personal healt...

Non-FDA-Approved Abortion Regimen Shows Efficacy

Dr Peter Kovacs summarizes the results of a study in which patients were given 200 mg mifepristone followed by 800 mcg misoprostol. Medscape Ob/Gyn

Milk thistle extract helps fight brain tumors

Provided by Marcelo Paez-Pereda, Max-Planck-Gesellschaft Cushing's Syndrome, is caused by a tumor in the pituitary gland in the brain. The tumor secretes increased amounts of the stress hormone adrenocorticotropin (ACTH) followed by cortisol release from the adrenal glands leading to rapid weight gain, elevated blood pressure and muscular weakness. Patients are prone to osteoporosis, infections a...



Advertisement
 
Advertisement
 

News Quicklinks